The 6 Injustices of Thyroid Cancer
Imagine if your best friend -- the one who deserves one hell of a co-pay for the psych-worthy advice she doles out on a daily basis (with love and/or or a swift kick in the butt, as needed) suddenly couldn't speak. My lifeline, Jill Gurfinkel, had a paralyzed vocal cord for what seemed like forever. Not from cheering for her then 7-year-old son at his hockey game or yelling at him to eat his vegetables or even from litigating in court (I don't mess around; my chief counsel is a badass lawyer). The only thing that has ever robbed her of her voice was thyroid cancer. In Cindy Finch's recent HuffPost blog, "The 6 Injustices of Cancer," she seems to suggest that thyroid cancer is like a spa day, complete with fluffy slippers, refreshing cucumber-infused water, and a detoxifying steam bath compared to other cancers. Nothing could be farther from the harsh reality of this insidious disease. Here are the six injustices of thyroid cancer: 1. It's not the "good cancer." Jill's doctor held her head down as he inserted eight needles into her neck to biopsy her two tumors. No anesthetic was involved... and that was just the beginning of her journey to hell. Soon after, she was in surgery to remove the right lobe of her thyroid. When the pathology results came back a week later, they weren't "good." One tumor was a papillary carcinoma and the other larger tumor was a rare form of thyroid cancer called Hurthle cell carcinoma. The rest of her thyroid had t...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: Available online 9 October 2020Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Klaudia Kulczynska-Figurny, James J. Bieker, Miroslawa Siatecka
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Publication date: Available online 10 October 2020Source: European UrologyAuthor(s): Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
CONCLUSIONS: Immunohistochemistry seems to be a promising option not only in clinical recognition, but also in the selection and monitoring of treatment effects. However, these methods have not yet recommended for routine clinical use. PMID: 33032462 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: Respiratory Medicine Case ReportsAuthor(s): Vipul Patel, Tilottama Majumdar, Isha Samreen, Harpreet Grewal, Thomas Kaleekal
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
More News: Alopecia | Anemia | Anesthesia | Anesthesiology | Blogging | Brain | Brain Cancers | Breast Cancer | Breast Carcinoma | Budgets | Cancer | Cancer & Oncology | Carcinoma | Cardiology | Depression | External Beam Therapy | Funding | Heart | Hormones | Hyperthyroidism | Hypothyroidism | Legislation | Medical Law | Men | Neurology | Nutrition | Pancreas | Pancreatic Cancer | Pathology | PET Scan | Thyroid | Thyroid Cancer | Ultrasound